60 Degrees Pharma Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Public

  • Employees
  • 3

Employees

  • Stock Symbol
  • SXTP

Stock Symbol

  • Share Price
  • $0.47
  • (As of Friday Closing)

60 Degrees Pharma General Information

Description

60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 1025 Connecticut Avenue North West
  • Suite 1000
  • Washington, DC 20036
  • United States
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 1025 Connecticut Avenue North West
  • Suite 1000
  • Washington, DC 20036
  • United States

60 Degrees Pharma Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

60 Degrees Pharma Stock Performance

As of 20-Nov-2026, 60 Degrees Pharma’s stock price is $0.47. Its current market cap is $2.1M with 4.48M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.47 $0.50 $0.46 - $8.62 $2.1M 4.48M 402K -$2.77

60 Degrees Pharma Financials Summary

As of 30-Sep-2026, 60 Degrees Pharma has a trailing 12-month revenue of $907K.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 13,288 7,672 7,599 13,705
Revenue 907 1,005 608 254
EBITDA (8,235) (7,278) (7,884) (1,427)
Net Income (8,349) (7,365) (7,947) (3,766)
Total Assets 3,094 5,366 5,759 7,784
Total Debt 150 153 156 173
Public Fundamental Data provided by Morningstar, Inc. disclaimer

60 Degrees Pharma Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore 60 Degrees Pharma‘s full profile, request access.

Request a free trial

60 Degrees Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science
Drug Discovery
Washington, DC
3 As of 2025

Parsippany, NJ
 

Madrid, Spain
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

60 Degrees Pharma Competitors (5)

One of 60 Degrees Pharma’s 5 competitors is Melinta Therapeutics, a Private Equity-Backed company based in Parsippany, NJ.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Melinta Therapeutics Private Equity-Backed Parsippany, NJ
Insud Pharma Corporation Madrid, Spain
AN2 Therapeutics Formerly VC-backed Menlo Park, CA
Nova Biologics Corporation Oceanside, CA
Ambagon Therapeutics Venture Capital-Backed Eindhoven, Netherlands
You’re viewing 5 of 5 competitors. Get the full list »

60 Degrees Pharma Patents

60 Degrees Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4698164-A1 Methods for the treatment and prevention of non-viral tick-borne diseases and symptoms thereof Pending 21-Apr-2023
EP-4698165-A1 Methods for the treatment and prevention of non-viral tick-borne diseases and symptoms thereof Pending 21-Apr-2023
EP-4698167-A1 Methods for the treatment and prevention of non-viral tick-borne diseases and symptoms thereof Pending 21-Apr-2023
US-20240390359-A1 Methods for the treatment and prevention of non-viral tick-borne diseases and symptoms thereof Pending 21-Apr-2023
US-20250073222-A1 Methods for the treatment and prevention of non-viral tick-borne diseases and symptoms thereof Pending 21-Apr-2023 A61K31/4706
To view 60 Degrees Pharma’s complete patent history, request access »

60 Degrees Pharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

60 Degrees Pharma ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view 60 Degrees Pharma’s complete esg history, request access »

60 Degrees Pharma FAQs

  • When was 60 Degrees Pharma founded?

    60 Degrees Pharma was founded in 2010.

  • Where is 60 Degrees Pharma headquartered?

    60 Degrees Pharma is headquartered in Washington, DC.

  • What is the size of 60 Degrees Pharma?

    60 Degrees Pharma has 3 total employees.

  • What industry is 60 Degrees Pharma in?

    60 Degrees Pharma’s primary industry is Drug Discovery.

  • Is 60 Degrees Pharma a private or public company?

    60 Degrees Pharma is a Public company.

  • What is 60 Degrees Pharma’s stock symbol?

    The ticker symbol for 60 Degrees Pharma is SXTP.

  • What is the current stock price of 60 Degrees Pharma?

    As of 20-Nov-2026 the stock price of 60 Degrees Pharma is $0.47.

  • What is the current market cap of 60 Degrees Pharma?

    The current market capitalization of 60 Degrees Pharma is $2.1M.

  • What is 60 Degrees Pharma’s current revenue?

    The trailing twelve month revenue for 60 Degrees Pharma is $907K.

  • Who are 60 Degrees Pharma’s competitors?

    Melinta Therapeutics, Insud Pharma, AN2 Therapeutics, Nova Biologics, and Ambagon Therapeutics are competitors of 60 Degrees Pharma.

  • What is 60 Degrees Pharma’s annual earnings per share (EPS)?

    60 Degrees Pharma’s EPS for 12 months was -$2.77.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process